Cardiff Oncology Inc (CRDF) Stock Price, Quote & News

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 7570

Website: www.cardiffoncology.com

Address:

11055 Flintkote Avenue, San Diego, United States

User123321 Jan. 30 at 3:58 PM

$CRDF No gap to fill. Hopefully this holds green today no matter what the market does but? 😀✌️👍🙏

0 · Reply

BilboBagginses Jan. 30 at 3:58 PM

$CRDF who said something about a 3-day rule?

0 · Reply

BubbaLubsGreen Jan. 30 at 3:50 PM

$CRDF might need an activist shareholder (or group of shareholders) at this point, to force management to behave in such a way as would reflect a serious sense of fiduciary duty to investors. I'm a believer in the mission, and I'm a believer in Onvansertib's value and potential to benefit patients. I'm just not a believer at this point in the actions of management being in the best interests of shareholders.

1 · Reply

Messerschmittbf109 Jan. 30 at 3:29 PM

$CRDF a …great manager destruction

0 · Reply

Harunkaraca Jan. 30 at 3:21 PM

$CRDF for me it Looks Like cheap

1 · Reply

Teskonik Jan. 30 at 3:15 PM

$CRDF ? ceo ? why new.

0 · Reply

Lord_Andrew_London Jan. 30 at 3:09 PM

$CRDF Erlander was able to drive the stock price From 25$ to 1,6$ in some years. A great performance. Frankly speaking I am Happy he's going......to hell.😁 Tell me why should I miss him.

2 · Reply

biohuntress Jan. 30 at 3:05 PM

$CRDF “We believe onvansertib, by inhibiting PLK1, has the potential to play a meaningful role in the treatment of several types of cancer, including the lead program in RAS-mutated mCRC,” said Dr. Schayowitz. “We believe that by combining Pfizer’s clinical development capabilities and expertise, with onvansertib’s promising novel clinical findings, we have an opportunity to accelerate the advancement of this program for the benefit of the many patients in the RAS-mutated mCRC setting.”......PFE designed the 004 trial which confirmed that the addition of ONVA to the mCRC FOLFIRI SOC benefits these pts...now PFE must take the next step and decide what is the path forward.....partnership, acquisition or chance losing a potential new SOC in mCRC ...this is their baby...what is it worth?

0 · Reply

Teskonik Jan. 30 at 3:04 PM

$CRDF looks found a bottom now.

0 · Reply

Lord_Andrew_London Jan. 30 at 2:58 PM

$CRDF What I really don't understand Is why people got so scared about management change. It's quite obvious that the new people Will be able to deliver. Such a stupid reaction.

2 · Reply

Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Jan 28, 2026, 2:12 AM EST - 2 days ago

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Jan 27, 2026, 7:05 AM EST - 3 days ago

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Jan 27, 2026, 7:00 AM EST - 3 days ago

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

CTMX

Jan 13, 2026, 10:48 AM EST - 17 days ago

Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm

Dec 8, 2025, 4:05 PM EST - 7 weeks ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Dec 8, 2025, 7:00 AM EST - 7 weeks ago

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Nov 24, 2025, 7:00 AM EST - 2 months ago

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 4:05 PM EST - 3 months ago

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Nov 4, 2025, 4:01 PM EST - 3 months ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Oct 25, 2025, 7:50 AM EDT - 3 months ago

Cardiff Oncology: Preparing For A Defining 2026

Oct 22, 2025, 7:45 AM EDT - 3 months ago

Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy

Aug 28, 2025, 4:05 PM EDT - 5 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Jul 30, 2025, 3:27 PM EDT - 6 months ago

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Jul 30, 2025, 11:32 AM EDT - 6 months ago

Cardiff Oncology: Data Update Resolves Some Signals

Jul 29, 2025, 4:07 PM EDT - 6 months ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jun 27, 2025, 8:30 AM EDT - 7 months ago

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Jun 17, 2025, 4:39 PM EDT - 8 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:05 PM EDT - 8 months ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 2, 2025, 4:05 PM EDT - 8 months ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

May 14, 2025, 9:05 AM EDT - 9 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 8, 2025, 4:05 PM EDT - 9 months ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 2, 2025, 3:35 AM EDT - 9 months ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 15, 2025, 4:10 PM EDT - 10 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:05 PM EDT - 10 months ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Feb 27, 2025, 9:10 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 24, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 18, 2025, 9:19 AM EST - 1 year ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Dec 12, 2024, 5:38 AM EST - 1 year ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 10, 2024, 5:05 PM EST - 1 year ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 7:20 AM EST - 1 year ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 6:00 AM EST - 1 year ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 4, 2024, 1:10 PM EDT - 1 year ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Aug 12, 2024, 2:57 PM EDT - 1 year ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Mar 8, 2024, 7:37 PM EST - 2 years ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 6, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Feb 29, 2024, 8:06 PM EST - 2 years ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

User123321 Jan. 30 at 3:58 PM

$CRDF No gap to fill. Hopefully this holds green today no matter what the market does but? 😀✌️👍🙏

0 · Reply

BilboBagginses Jan. 30 at 3:58 PM

$CRDF who said something about a 3-day rule?

0 · Reply

BubbaLubsGreen Jan. 30 at 3:50 PM

1 · Reply

Messerschmittbf109 Jan. 30 at 3:29 PM

$CRDF a …great manager destruction

0 · Reply

Harunkaraca Jan. 30 at 3:21 PM

$CRDF for me it Looks Like cheap

1 · Reply

Teskonik Jan. 30 at 3:15 PM

$CRDF ? ceo ? why new.

0 · Reply

Lord_Andrew_London Jan. 30 at 3:09 PM

$CRDF Erlander was able to drive the stock price From 25$ to 1,6$ in some years. A great performance. Frankly speaking I am Happy he's going......to hell.😁 Tell me why should I miss him.

2 · Reply

biohuntress Jan. 30 at 3:05 PM

0 · Reply

Teskonik Jan. 30 at 3:04 PM

$CRDF looks found a bottom now.

0 · Reply

Lord_Andrew_London Jan. 30 at 2:58 PM

$CRDF What I really don't understand Is why people got so scared about management change. It's quite obvious that the new people Will be able to deliver. Such a stupid reaction.

2 · Reply

lonedaddy Jan. 30 at 2:57 PM

$CRDF The new leadership needs to clarify the situation ASAP and explain why Erlander is an independent director now. It is Bordering on negligence. The silence is what is killing the stock. Clarity is needed, hopefully they get their shit together by Monday. I'm also assuming they are doing a compensation deal for the Muni and the promotion.

1 · Reply

rag2riches Jan. 30 at 2:57 PM

$CRDF and no i havent sold a share. Im bag holding now and would like to average down but not yet until its clear how they are going to fianace the phase 3 and their expansion of the clinical development team and new C suites which is not cheap. Commericialization is not cheap. Ill wait for the heavy dilution unless theres a partneship

1 · Reply

rag2riches Jan. 30 at 2:54 PM

$CRDF they got rid of their CMO, and now CFO and CEO. The sudden departure of the CEO/CFO is very concerning to me. The truth may not be known and no matter how you look at it. When you clear house with the most important C suites its never net positive. Interim CEO is in full spin mode to highlights the positive which is the FOLFIRI combo but even then they only shared a snippet of the data and keen analysts noticed it wasnt fully BICR data. Based on my onpinion, the bev combo hypthesis failed which is why they replaced the CMO. The CEO and CFO sudden departure indicates to me a failed partnership or financing. CEO saying no strings attached could have been a sign of desperation and the CFO was not avle to capitalize and essentially let commodore capital an easy quick flip and diluted us. At the end of the day im in bearish in the short term because alot of this doesnt seem positive, but i still believe there is potential with FOLFIRI

1 · Reply

Messerschmittbf109 Jan. 30 at 2:47 PM

$CRDF fact is that this stock is timbering every day

1 · Reply

JanetBSmellin Jan. 30 at 12:49 PM

$CRDF Did your Daddy/Uncle tell you that?

1 · Reply

Mdmsi1 Jan. 30 at 10:31 AM

$CRDF This week crdf went from clinical validation phase to capital markets and regulatory execution phase, that’s a very different job and most probably the reason why they canned ceo and cfo, right drug wrong executives for phase 3, per ChatGPT.

2 · Reply

Milkman78 Jan. 30 at 8:20 AM

$CRDF @suphawk85 The recent selloff looks driven more by uncertainty and optics than any failure of the science. The update reaffirmed dose-dependent efficacy, with the 30mg arm showing strong confirmed ORR, favorable hazard ratio, and median PFS not reached, supporting its selection for a registrational path. These results are consistent with prior ONSEMBLE data and validate onvansertib’s activity in 1L RAS-mutant mCRC. What rattled the market was execution: a partial update, lack of full KM curves, and simultaneous CEO/CFO transitions. Small biotechs often get punished disproportionately for that, even when data are directionally positive. As PFS matures and FDA discussions clarify next steps (seamless trial / AA optionality), fundamentals should reassert themselves. The recent price action reflects confusion and risk repricing, not a negation of the drug’s potential.

0 · Reply

suphawk85 Jan. 30 at 5:28 AM

$CRDF Talk about a kick in the teeth when we're already down so much. Reading this simply wallst assessment really hurts 🤕 https://finance.yahoo.com/news/cardiff-oncology-crdf-down-43-111213289.html

3 · Reply

bioprof2 Jan. 30 at 3:38 AM

$CRDF FYI: Erlander and Levine both have double-trigger (not single-trigger) CIC clauses with a double-sided 12-month window in their employment contracts (see filings). To receive their: (1) accelerated equity, (2) 1 yr salary, (3) 1 yr bonus, (4) benefits + accrued comp Both triggering events must occur: 1. Change of Control AND 2. Termination w/o cause or resignation for Good Reason. Trigger #2 occurred Tuesday... I’ll leave it at that.

4 · Reply

Core366 Jan. 30 at 3:35 AM

$CRDF https://www.nasdaq.com/articles/trovagene-plunges-on-ceo-and-cfo-dismissal-files-suit-2016-03-29 History repeats itself. Cardiff was Trovagene previously and terminated its ceo and cfo, stock plunged lol

1 · Reply

bioprof2 Jan. 30 at 1:50 AM

$CRDF The CEO/CFO change had to happen now to pivot the company toward M&A. The data release served as a buffer for investors (albeit limited) and, more importantly, as an advertisement to potential acquirers - the conversation had to start somewhere. A $1+ drop feels dramatic, but in biotech that same stock can jump $5 on a single deal rumor. Biotechs in the midst of being sold aren't ones to hold short over the weekend, especially when the technicals have an RSI below 28.

1 · Reply

biohuntress Jan. 29 at 11:00 PM

$CRDF further clarification...Both FDA Breakthrough Therapy and Accelerated Approval are designed to speed up the drug approval process, but Breakthrough Therapy typically allows for a faster development and review process, often resulting in quicker access to promising treatments. However, Accelerated Approval can also expedite access based on surrogate endpoints, which may lead to faster initial approvals for certain drugs.

0 · Reply

Market Cap	109.13M
Revenue (ttm)	680,000.00
Net Income (ttm)	-45.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,680.88%
Debt to Equity Ratio	0.00

Volume	3,391,300
Avg Vol	1,306,478
Day's Range	N/A - N/A
Shares Out	67.36M
Stochastic %K	0%
Beta	1.40
Analysts	Strong Sell
Price Target	$10.25